Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation
Open Access
- 21 May 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 40 (8), 768-773
- https://doi.org/10.1093/jjco/hyq055
Abstract
ObjectiveSorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials. The efficacy and safety of sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation, however, has not been determined.MethodsWe retrospectively analyzed 13 patients who were treated with sorafenib for recurrent hepatocellular carcinoma after liver transplantation.ResultsThe median time to recurrence from liver transplantation was 12.3 months (95% confidence interval: 8.5–16.1 months). Six of 10 evaluable patients showed stable disease, which was the best response and the median duration of stabilization was 3.9 months (95% confidence interval: 1.6–6.2 months). At a median follow-up duration of 3.7 months (range: 0.3–10.9 months) in surviving patients, the median time to progression and the median overall survival from commencement of sorafenib were 2.9 months (95% confidence interval: 0.0–6.8 months) and 5.4 months (95% confidence interval: 3.7–7.0 months), respectively. Grade 3 neutropenia was observed in one patient, which was the only high-grade hematologic toxicity observed. Grade 3 hand-foot skin reactions were observed in three patients. Adverse events could be managed with dose adjustment.ConclusionsThese findings suggest that sorafenib may be a feasible treatment option regarding its efficacy and safety for recurrent hepatocellular carcinoma after liver transplantation.Keywords
This publication has 15 references indexed in Scilit:
- Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantationJournal of Gastroenterology and Hepatology, 2009
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume centerLiver Transplantation, 2008
- Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Patterns and Prognostic Factors Based on Clinical and Radiologic FeaturesAmerican Journal of Roentgenology, 2007
- Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver TransplantationKorean Journal of Radiology, 2007
- Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma?Journal of Hepatology, 2005
- How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?Journal of Hepatology, 2005
- Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosisLiver Transplantation, 2004
- Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantationCancer, 1991